Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 23 of 116

  1. Telisotuzumab Vedotin, DOCETAXEL

    AbbVie Deutschland GmbH & Co. KG

    c-Met overexpressing EGFR wildtype non-squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  2. Thalidomide

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 3 small molecule completed

    1 trial

  3. The placebo tablet composition is: Collodial...

    The George Institute

    Colon and rectal cancer tumor stage II-III, tumor with somatic alterationsin PIK3CA, PIK3R1 or PTEN

    phase 3 small molecule active

    1 trial

  4. Tiaoshen Anti-cancer Granules

    The First People's Hospital of Lianyungang

    Ovarian Neoplasms Malignant

    phase 3 small molecule active

    1 trial

  5. Tibsovo 250 mg film-coated tablets

    The George Institute

    ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma

    phase 3 small molecule active

    1 trial

  6. Tinidazole oral microneedle patch

    The First People's Hospital of Lianyungang

    Evaluate the DFS of Patients With Esophageal Cancer Who Underwent Radical Operation After Regular Removal of Porphyromonas Gingivalis

    phase 3 other active

    1 trial

  7. Tiragolumab

    Hoffmann-La Roche

    Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  8. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Non Small Cell Lung Cancer

    phase 3 small molecule active

    4 trials

  9. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Classical Hodgkin Lymphoma

    phase 3 small molecule terminated

    1 trial

  10. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Urothelial Carcinoma

    phase 3 small molecule active

    1 trial

  11. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Rectal Carcinoma

    phase 3 small molecule active

    1 trial

  12. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 3 small molecule completed

    1 trial

  13. Tislelizumab

    BeiGene

    Recurrent or Metastatic Nasopharyngeal Cancer

    phase 3 small molecule completed

    1 trial

  14. Tislelizumab

    BeiGene

    Non-small Cell Lung Cancer

    phase 3 small molecule completed

    2 trials

  15. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colonic Neoplasms

    phase 3 small molecule active

    1 trial

  16. Tislelizumab

    The First People's Hospital of Lianyungang

    Rectal Neoplasms

    phase 3 small molecule active

    1 trial

  17. Tislelizumab + SOX Chemotherapy

    The First People's Hospital of Lianyungang

    Gastric Cancer Stage III

    phase 3 small molecule active

    1 trial

  18. Tislelizumab（neoadjuvant）

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinomas

    phase 3 small molecule active

    1 trial

  19. Tora-Dol /ml soluzione iniettabile for Patients scheduled for major su…

    Fondazione Telethon ETS

    Patients scheduled for major surgery for oncologic indication

    phase 3 small molecule active

    1 trial

  20. Toripalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    2 trials

  21. Toripalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  22. Trabectedin

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Ovarian Cancer

    phase 3 small molecule completed

    1 trial

  23. Trastuzumab

    Celltrion Healthcare Australia Pty Ltd

    HER2-positive Carcinoma of Breast

    phase 3 small molecule completed

    1 trial

  24. Trastuzumab

    Hoffmann-La Roche

    Metastatic Breast Cancer

    phase 3 small molecule terminated

    1 trial

  25. Trastuzumab

    Mylan IRE Healthcare Limited

    Breast Cancer

    phase 3 mab completed

    1 trial

  26. Trastuzumab Deruxtecan

    Daiichi Sankyo

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  27. Trastuzumab Deruxtecan

    AstraZeneca

    Breast Neoplasms

    phase 3 small molecule active

    1 trial

  28. Trastuzumab Deruxtecan

    AstraZeneca

    Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  29. Trastuzumab Deruxtecan

    Daiichi Sankyo

    Ovarian Cancer

    phase 3 small molecule active

    1 trial

  30. Trastuzumab Deruxtecan

    Daiichi Sankyo

    Gastric Cancer

    phase 3 small molecule active

    1 trial

  31. Trastuzumab Emtansine

    Hoffmann-La Roche

    Metastatic Breast Cancer

    phase 3 small molecule terminated

    1 trial

  32. Trastuzumab and neratinib

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    Early-stage Breast Cancer

    phase 3 small molecule active

    1 trial

  33. Trastuzumab deruxtecan

    AstraZeneca

    Breast Cancer; HER2-positive; Metastatic

    phase 3 small molecule active

    1 trial

  34. Trastuzumab deruxtecan

    AstraZeneca

    Advanced or Metastatic Breast Cancer

    phase 3 small molecule active

    1 trial

  35. Trastuzumab emtansine

    Hoffmann-La Roche

    Breast Cancer

    phase 3 small molecule completed

    3 trials

  36. Tremelimumab

    AstraZeneca

    Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  37. Tropion-Breast05

    AstraZeneca AB

    Triple-negative Breast Cancer

    phase 3 small molecule active

    1 trial

  38. Two Anti-angiogenesis Drugs（Endostar and Thalidomide）

    The First People's Hospital of Lianyungang

    Colorectal Neoplasms

    phase 3 small molecule active

    1 trial

  39. Tyrosine kinase inhibitor (TKIs)

    The First People's Hospital of Lianyungang

    Philadelphia Chromosome Positive Acute Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  40. U31402-A-U301

    Daiichi Sankyo

    Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  41. UC-0103/1102

    Ningbo Cancer Hospital

    oestrogen-receptor (ER)-positive HER2-negative breast carcinoma

    phase 3 small molecule active

    1 trial

  42. UC-0103/1802

    Ningbo Cancer Hospital

    Advanced or metastatic soft tissue sarcoma (STS) in patients ≥65 years old

    phase 3 small molecule active

    1 trial

  43. UC-0110/1609

    Ningbo Cancer Hospital

    High-risk stage III colon cancer

    phase 3 small molecule active

    1 trial

  44. UC-0140/1615

    Ningbo Cancer Hospital

    ER+/HER2- metastatic breast cancer

    phase 3 small molecule active

    1 trial

  45. UC-0140/1901

    Ningbo Cancer Hospital

    Patients with untreated metastatic Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor-2 negative (HER2-) breast cancer with visceral involvement

    phase 3 small molecule active

    1 trial

  46. UC-BCG-2409/BIG 2402

    Ningbo Cancer Hospital

    Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply: a. 1-3 lymph nodes involved AND any invasive tumour size. b. node negative (including micrometastases in at least 1 node [i.e. deposit >0.2-2mm diameter]) AND invasive tumour size ≥ 50mm.

    phase 3 small molecule active

    1 trial

  47. UC-BCG-2501

    Ningbo Cancer Hospital

    Patients with HR+ HER2- early breast cancer at intermediate risk of recurrence and eligible for adjuvant chemotherapy

    phase 3 small molecule active

    1 trial

  48. UC-GIG-2406

    Ningbo Cancer Hospital

    Patients with hepatocellular carcinoma with high tumor burden.

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.